Intellect Neurosciences Inc. (fka ILNS)

[Stately]

Nothing new, but thank you for the DD. If anything, Shire is moving at your typical corporate pace in making decisions about it, but it's at least a good sign that the trial ended 10 months ago and they still consider it part of the pipeline.

Personally I think the recent activity coincides more suspiciously with the wrapping up of the Prizer ponezumab trial for CAA. I'm guessing we hear something about that trail in the next month or two.